Kestra Medical Technologies (NASDAQ:KMTS) Director Conor Hanley Sells 5,694 Shares

by · The Cerbat Gem

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) Director Conor Hanley sold 5,694 shares of Kestra Medical Technologies stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $25.25, for a total transaction of $143,773.50. Following the completion of the transaction, the director directly owned 6,272 shares in the company, valued at $158,368. This represents a 47.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Down 2.1%

NASDAQ:KMTS traded down $0.50 during trading hours on Thursday, reaching $23.57. 310,496 shares of the company’s stock were exchanged, compared to its average volume of 240,413. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a 12 month low of $17.34 and a 12 month high of $30.00. The business’s 50-day simple moving average is $25.42 and its two-hundred day simple moving average is $22.71.

Kestra Medical Technologies (NASDAQ:KMTS – Get Free Report) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Sell-side analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on KMTS shares. JPMorgan Chase & Co. started coverage on shares of Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 target price on the stock. Weiss Ratings lowered shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, August 31st. Wall Street Zen raised shares of Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a research note on Tuesday, July 21st. They set a “market perform” rating for the company. Finally, BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Kestra Medical Technologies in a report on Wednesday, September 2nd. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $28.14.

Get Our Latest Research Report on KMTS

Institutional Investors Weigh In On Kestra Medical Technologies

Several institutional investors and hedge funds have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in shares of Kestra Medical Technologies during the 1st quarter worth about $11,036,000. Woodline Partners LP acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth approximately $2,510,000. Jane Street Group LLC acquired a new stake in shares of Kestra Medical Technologies during the first quarter worth approximately $756,000. Geode Capital Management LLC raised its stake in shares of Kestra Medical Technologies by 718.5% in the second quarter. Geode Capital Management LLC now owns 325,326 shares of the company’s stock valued at $5,395,000 after acquiring an additional 285,579 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in Kestra Medical Technologies in the 2nd quarter valued at $256,000.

Kestra Medical Technologies Company Profile

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

Read More